Literature DB >> 12426051

The role of histamine in dural vessel dilation.

Simon Akerman1, David J Williamson, Holger Kaube, Peter J Goadsby.   

Abstract

The pain of migraine is often throbbing suggesting an important role for the cranial blood vessels and their innervation by the trigeminal nerve. It is proposed that clinically effective anti-migraine compounds, such as 5-HT(1B/1D) agonists, have actions that include inhibiting calcitonin gene-related peptide (CGRP) release from trigeminal nerves. Human studies suggest that histamine can induce migraine possibly by activating nitric oxide (NO) synthase to promote endogenous NO production. The present studies investigated the effect of histamine and its antagonists on the cranial blood vessels using intravital microscopy to assess directly the diameter of dural arteries in sodium pentobarbitone anaesthetised rats. Electrical stimulation of a closed cranial window produces, by local depolarisation of nerves, dural vessel dilation that is monitored continuously on-line using video-microscopy and a video dimension analyser. Histamine infusion caused immediate and reproducible dilation of meningeal blood vessels (103.5+/-6%; n=40) that could be blocked by H(1)- (mepyramine) and H(2) (famotidine)-receptor antagonists (P<0.05), as well as a nitric oxide synthase inhibitor (N(G)-nitro-L-arginine methylester; P<0.05). Neurogenic dural vasodilation was not inhibited by H(2)-receptor antagonists, but was significantly inhibited by a H(1)-receptor antagonist at the high dose of 10 mg/kg. The present studies demonstrate that histamine is likely to activate NO synthase to promote NO production. There is also evidence that H(1)-receptors may be present on trigeminal neurones as the H(1)-receptor antagonist inhibited neurogenic vasodilation, albeit at a large dose.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12426051     DOI: 10.1016/s0006-8993(02)03485-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

Review 2.  Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches.

Authors:  Peter J Goadsby
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Prophylactic activity of increasing doses of intravenous histamine in refractory migraine: Retrospective observations of a series of patients with migraine without aura.

Authors:  Umberto Pietrini; Massimo De Luca; Enrico Del Bene; Francesco De Cesaris; Luca Bertinotti; Nicola Colangelo; Alberto Moggi Pignone
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

Review 4.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

Review 5.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 6.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

7.  Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds.

Authors:  Gustaf Grände; Sieneke Labruijere; Kristian Agmund Haanes; Antoinette MaassenVanDenBrink; Lars Edvinsson
Journal:  J Headache Pain       Date:  2014-04-23       Impact factor: 7.277

Review 8.  Advances in Meningeal Immunity.

Authors:  Rejane Rua; Dorian B McGavern
Journal:  Trends Mol Med       Date:  2018-05-03       Impact factor: 11.951

Review 9.  Fatigue, Sleep, and Autoimmune and Related Disorders.

Authors:  Mark R Zielinski; David M Systrom; Noel R Rose
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.